Cord Blood America, Inc.(CBAI), through its wholly owned subsidiary CorCell Companies, Inc., is engaged in the business of collecting, testing, processing and preserving umbilical cord blood, thereby allowing families to preserve cord blood at the birth of a child for potential use in future stem cell therapy. http://www.cordblood-america.com/
NEW CEO The entire interview is available
Cord Blood America, Inc "Companies"
September 30,2012,-249,999,364====Cash $369,186 Increase
June 30, 2012,-----249,999,364====Cash $332,928 Increase
March 31, 2012,----249,999,364====Cash $300,619 Increase
Assets Over $7million
2012: almost $6million
Share Outstanding= last known 643million with 890 a/s
Operating on its own cash= YES
Cash flow= 369,186
NEW DEBT ISSUED= NO
Operating on it own cash=NO
Shares outstanding 5.6 Billion shares
$66million market cap
Operating on it own cash= NO
Cash Flow= $236K
New Debt issued= YES
2009: $3,237,183==$30million market cap==
PR September 26, 2012 commented Joseph Vicente, President of Cord Blood America. "We are now cash flow positive
so the announced approval to increase our authorized shares is primarily to fix legacy issues
. Operating activities have already shown marked sequential and year over year improvement while reducing corporate costs creating an advantageous time to improve the capital structure and bring the Company to the next level while broadening its appeal to a wider audience of potential investors." http://ih.advfn.com/p.php?pid=nmona&article=54314478
Nine-Months Ended September 30, 2012 Highlights
=====Revenue increase 18% to $4.64 million from $3.93 million in the year ago period.
=====Our cash position increased over 100% to $369,186.
=====Gross margin increased to 72.7% from 70.5% in the year ago period.
=====SG&A decreased 24% or $1.17 million to $3.64 million from $4.81 million.
For the second consecutive quarter, we demonstrated marked improvement in three key performance metrics; revenue growth, expense control and EBITDA. The result is that we have improved our cash position, while reducing the current liabilities without adding to the debt obligations of the Company. We continue to see consistent growth in the number of new customers added each quarter that will layer on top of our existing recurring revenue base. We expect our new customers to have an annual recurring duration of approximately eighteen years demonstrating the significant lifetime value of each new client," commented Joseph Vicente, President of Cord Blood America, Inc. Share Structure
Projected SS:: Since September 30 2012 1.117 Billion shares have traded, based on statistics from the past 65% of shares trades would contribute to the outstanding = 726 Million shares outstanding as/of 03/13/2013
Finally, CBAI's President said that although the Company's financial situation has improved and the Company did not take any additional financing in Q2, it is not generating enough cash to pay off its entire debt balance. He urged shareholders to approve an increase in the number of authorized shares "as a means to retire out legacy debt and move forward." http://ih.advfn.com/p.php?pid=nmona&article=53904255 Insurance Partners
Blue Cross Blue ShieldOur current healthcare partners listed below have negotiated a special program for our customers to save cord blood for their children, grandchildren, nieces, nephews, friends or other loved ones. To learn more about our insurance partners visit the CorCell® website at www.corcell.com.
Blue Cross of Idaho's https://www.bcidaho.com/Health_Wellness/discount%20services/CorCell.asp
Asuris Northwest Health
Blue Cross Blue Shield of Kansas
Blue Cross Blue Shield of Northeastern Pennsylvania
Highmark Blue Cross Blue Shield West Virginia
HMSA - Blue Cross Blue Shield of Hawaii
Horizon Blue Cross Blue shield of New Jersey
Independence Blue Cross
Keystone, Personal Choice (part of IBC, and BCBS of North Eastern PA)
LifeWise Assurance Company
LifeWise Health Plan of Oregon
LifeWise Health Plan of Washington
Premera Blue Cross
Permera Blue Cross Blue Shield of Alaska
Regence Blue Shield
Regence BlueCross Blue Shield of Oregon
Regence BlueCross Blue Shield of Utah
Regence BlueCross Blue President
Joe has been a Director of Cord Blood America since April 2004. Additionally, he currently serves as the President. Prior to joining us Joe was an independent consultant where he provided strategic consulting services to organizations on acquisitions, operational practices and efficiencies, and sales management. He was a Senior Vice President at TMP Worldwide, Inc. where he held various positions with profit and loss responsibility.
Joe graduated from Bowling Green State University with a BSBA and from University of Tampa with an MBA. Joseph Vicente Primarily involved in Mergers & Acquisitions, Corporate Governance
(702) 914-7250 [email protected] http://www.linkedin.com/pub/joseph-vicente/9/90/93a The entire interview is available
__________________________________________________________________________________________________________________________________________________ Vice President & General Counsel
Stephen Morgan currently serves as Vice President, General Counsel, and Secretary. He has been General Counsel of the Company since August 2010. Prior to his employment with the Company, Mr. Morgan worked for law firms in Los Angeles, California, representing clients in a broad range of transactional and litigation matters. Mr. Morgan earned his Bachelor of Science degree from the University of Minnesota and his Juris Doctor from Loyola Law School in Los Angeles, California.
(702) 914-7250 [email protected] [email protected][email protected]
________________ Tissue Bank Director
Dr. O'Neill has 25 years experience in the industry, processed more than 50,000 specimens and has published 78 papers. Educated at the University of Glasgow in Scotland, Dr. O'Neill came to the United States in 1979 to work for the Memorial Sloan-Kettering Cancer Center in New York. While continuing to work in the field his experience continued to grow as he also was a Professor at various prestigious universities including:
Cornell University school of Medicine, NY;
Columbia University, NY;
Visiting Professor at the Institute of Immunology in Munich
Dr. Geoffrey O'Neill
(702) 914-7250 [email protected]
more pictures ::: https://www.facebook.com/photo.php?fbid=10150787074433828&set=pb.345311198827.-2207520000.1363407258&type=3&theater